

# Report from the EBA Working Group on innovation and new products subgroup on blood products for major haemorrhage

Tor

**Torunn Oveland Apelseth, MD, PhD**

Director, Norwegian Center for Blood Preparedness,  
Senior Consultant, Department of Immunology and Transfusion Medicine, Haukeland University Hospital,  
Bergen, Norway  
Associate Professor University of Bergen, Norway  
Senior Advisor, Norwegian Armed Forces Joint Medical Services

E-mail: [torunn.oveland.apelseth@helse-bergen.no](mailto:torunn.oveland.apelseth@helse-bergen.no)

27. januar 2023



## MEMBERS OF THE GROUP

Torunn Oveland Apelseth<sup>1,2,3</sup>, Barry Doyle<sup>4</sup>, Ryan Evans<sup>5</sup>, Chloe George<sup>6</sup>, Catherine Humbrecht<sup>7</sup>, Thomas Klei<sup>8</sup>, Tome Najdovski<sup>9</sup>, Ólafur Eysteinn Sigurjónsson<sup>10,11</sup>, Michael Wiltshire, Dirk de Korte<sup>8,13</sup>

### AFFILIATIONS

Department of Immunology and Transfusion Medicine, Haukeland University Hospital, Bergen, Norway

Department of Clinical Science, University of Bergen, Bergen, Norway

Norwegian Armed Forces Joint Medical Services, Oslo, Norway

Irish Blood Transfusion Service, Dublin, Republic of Ireland

Scottish National Blood Transfusion Service, Edinburgh, Scotland

Welsh Blood Service, Llantrisant, Wales

Etablissement Français du Sang Grand Est, Nancy, France

Sanquin Blood Bank, Amsterdam, The Netherlands

Service du Sang, Suarlée, Belgium

The Blood Bank, Landspítali- University Hospital, Reykjavik, Iceland

Reykjavik University, Reykjavik, Iceland

NHS Blood and Transplant, Cambridge, UK

Department Blood Cell Research, Sanquin Research, Amsterdam, the Netherlands



## BACKGROUND

When we started this work, we were in the middle of the COVID19 pandemic.  
Now we have war in Europe.




Photo: Public domain



Photo: Kai Pfaffenbach/Reuters/NTB




# INCREASED FOCUS ON BLOOD PREPAREDNESS

There is a need to plan for emergency preparedness and management of patients with massive haemorrhage.

<https://www.edqm.eu/en/blood-supply-contingency-and-emergency-plan-b-scep>

*Published May 2022*



## WHY DO WE NEED TO CONSIDER NEW BLOOD PRODUCTS FOR PATIENTS WITH MASSIVE HAEMORRHAGE?

It is our responsibility as blood providers to always strive to improve our service and to provide enough blood and the best blood products for our patients.

We need to know how to support blood under difficult circumstances.

..... So maybe we have something to learn from the past. For our «new» blood products are not always new...



FIGURE 4.—British and Canadian materials and equipment for replacement therapy. A. British (right) and U.S. Army dried plasma units. B. British depressing set for plasma.




FIGURE 108.—Blood transfusion in forward hospital in Seventh U.S. Army, Besançon area, France, September 1944.



# SURVEY OF CURRENT PRACTICE AND NEED FOR NEW OR MODIFIED BLOOD PRODUCTS

Survey of the current transfusion practise in Europe and the need for new blood products to ensure adequate blood supply for patients with massive haemorrhage.



The screenshot shows the EBA logo with the tagline 'Safe blood for Europe' in the top left corner. The main title of the survey is 'Blood products for major haemorrhage\_Current practices'. Below the title, there is a 'Background' section explaining that the survey is an initiative of the EBA Innovation and New Products Working Group, aimed at describing the approach to managing major haemorrhage in EBA member states and identifying the need for new blood products. It also states that the information obtained will be included in a report and presented to the EBA leadership and members, and that a summary of the results may be published in a peer-reviewed medical journal. The survey is divided into two sections: '1. Your Contact details' and '2. Approval for the use of data \*'. Section 1 contains four input fields: 'Country', 'Organisation/Blood Establishment', 'Name', and 'Email'. Section 2 contains three checkboxes: 'I approve that the data reported can included in the report to EBA members and members from the Innovation and New Products Working Group', 'I approve that the data reported can be published in a peer-reviewed medical journal.', and 'I do not approve that the data reported can be published in a peer-reviewed medical journal.'. A red 'Next' button is located at the bottom right of the form.

**eba**  
Safe blood for Europe

## Blood products for major haemorrhage\_Current practices

### Background

This survey is an initiative of the EBA Innovation and New Products Working Group. The aim of the survey is to describe the approach to managing major haemorrhage in the EBA member states, and to identify whether there is a need for new blood products for treatment of patients with major haemorrhage.

The information obtained in this survey will be included in a report and presented to the EBA leadership and members. In addition, a summary of the results may be published in a peer-reviewed medical journal. Please indicate below your approval for the use of data:

1. Your Contact details

Country

Organisation/Blood Establishment

Name

Email

2. Approval for the use of data \*

☐ I approve that the data reported can included in the report to EBA members and members from the Innovation and New Products Working Group

☐ I approve that the data reported can be published in a peer-reviewed medical journal.

☐ I do not approve that the data reported can be published in a peer-reviewed medical journal.

Next



## SURVEY QUESTIONS

1. How is your Blood Service organized?
2. Does your country have a standardized approach to managing major haemorrhage?
3. Does your recommendations include different approaches for different type of patients with major haemorrhage
4. Recommendations in current medical guidelines?
5. Use of Massive Transfusion Packages (MTPs)?
6. Which RhD type are used?
7. Do you provide blood products for prehospital transfusion?
8. Haemostatic agents (TXA, Ca, PCC, etc.)?
9. Implementation of modified blood components during the pandemics?
10. In your personal opinion, is there a need for implementation of new or modified blood components/products in your institution?





## RESULTS

Response rate: 65% (17 of 26 member states).

- Germany, Denmark, Sweden, The Netherlands, Portugal, Belgium, Norway, Slovenia, Estonia, Iceland, Ireland, England, Wales, Scotland, Italy, France, Switzerland

10/17 (60%) national standardized approach to managing major haemorrhage

3/17 (18%) standardized approach for each institution

4/17 (24%) no standardized approach to managing major haemorrhage


Use of massive transfusion packages (MTPs):

- 16/17 (94%) provide Massive Transfusion Packages (MTPs).
- The content of the MTPs vary between countries and between institutions within countries.
- 9/17 (53%) recommend that platelets are included from the start of treatment.






**FIGURE 1. CURRENT STATUS:  
BLOOD PRODUCTS FOR PREHOSPITAL TRANSFUSION**



## FIGURE 2. NEW BLOOD PRODUCTS OF INTEREST FOR TREATMENT OF PATIENTS WITH MAJOR HAEMORRHAGE

12/17 (70%) MEMBER STATES ANSWER THAT THERE IS A NEED FOR NEW PRODUCTS



## SUMMARY

- Recent events require a focus on blood supply planning to ensure an adequate supply of blood products for patients with massive haemorrhage on all treatment levels, including prehospital and in hospital care.
- This report describes the current transfusion practise in Europe and the perceived need for new or modified blood products.
- The survey reveals an interest in implementation of new or modified blood products, with whole blood, cold stored platelets and dried plasma being the three top priorities.



## NEXT STEPS



Use information from webinar and feedback from participants :

- Guideline on the implementation of whole blood for transfusion

Topics:

Indication for transfusion, Donor selection and release criteria, Production, Storage, Transport, Inventory management, Regulatory affairs, Post-implementation follow up, Validation



**Questions or comments?**

GÓ' PÅ BLÖD!

